{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:27:22Z","timestamp":1771046842329,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1889,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1111\/jth.13771","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T03:46:46Z","timestamp":1499485606000},"page":"1737-1746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-0358","authenticated-orcid":false,"given":"T.","family":"Preijers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-0582","authenticated-orcid":false,"given":"H.C.A.M.","family":"Hazendonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13771_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1111\/jth.13771_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.9.s1.4.x","article-title":"Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective","volume":"9","author":"Bjorkman","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl. 4","key":"10.1111\/jth.13771_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2516.2012.02838.x","article-title":"Personalized prophylaxis","volume":"18","author":"Collins","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2516.2001.00465.x","article-title":"Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis","volume":"7","author":"Bjorkman","year":"2001","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1111\/jth.13771_bb0030","first-page":"59","article-title":"Aspects of prophylactic treatment of hemophilia","volume":"14","author":"Ljung","year":"2016","journal-title":"Thromb J"},{"issue":"Suppl. 1","key":"10.1111\/jth.13771_bb0035","first-page":"S27","article-title":"Importance of pharmacokinetics in the management of hemophilia","volume":"60","author":"Barnes","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.13771_bb0040","unstructured":"Lee M, Morfini M, Schulman S, Ingerslev J, and the Factor VIII\/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. 2001. https:\/\/www.isth.org\/members\/group_content_view.asp?group=100348&id=159244. Accessed 15 December 2015."},{"key":"10.1111\/jth.13771_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bjorkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/FTD.0b013e3180311384","article-title":"A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A","volume":"29","author":"Bolon\u2010Larger","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jth.13771_bb0055","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/jth.13271","article-title":"Population pharmacokinetics of plasma\u2010derived factor IX: procedures for dose individualization","volume":"14","author":"Brekkan","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/clpt.2010.114","article-title":"Clinical trial simulation: a review","volume":"88","author":"Holford","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.13771_bb0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-200140010-00002","article-title":"A brief introduction to Monte Carlo simulation","volume":"40","author":"Bonate","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13771_bb0070","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/jth.13662","article-title":"Population pharmacokinetics of recombinant coagulation factor VIII\u2010SingleChain in patients with severe hemophilia A","volume":"15","author":"Zhang","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0075","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/jth.13444","article-title":"Population pharmacokinetics of a new long\u2010acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B","volume":"14","author":"Zhang","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.13109","article-title":"Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates","volume":"168","author":"Powell","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13771_bb0085","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00228-009-0699-3","article-title":"Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV\u2010negative and HIV\u2010positive haemophilia patients","volume":"65","author":"Karafoulidou","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.13771_bb0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/hae.12605","article-title":"Recombinant full\u2010length factor VIII (FVIII) and extended half\u2010life FVIII products in prophylaxis \u2013 new insight provided by pharmacokinetic modelling","volume":"21","author":"Gringeri","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/17474086.2014.951322","article-title":"Alprolix (recombinant Factor IX Fc fusion protein): extended half\u2010life product for the prophylaxis and treatment of hemophilia B","volume":"7","author":"Ducore","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1111\/jth.13771_bb0100","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jth.12000","article-title":"Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9\u2010GP), a glycoPEGylated recombinant factor IX","volume":"10","author":"Collins","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199937010-00003","article-title":"Population pharmacokinetics. A regulatory perspective","volume":"37","author":"Sun","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13771_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01061870","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data","volume":"11","author":"Sheiner","year":"1983","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/jth.13771_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00003088-199834010-00003","article-title":"Model\u2010based, goal\u2010oriented, individualised drug therapy. Linkage of population modelling, new \u2018multiple model\u2019 dosage design, bayesian feedback and individualised target goals","volume":"34","author":"Jelliffe","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13771_bb0120","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1345\/aph.1E259","article-title":"Population pharmacokinetics II: estimation methods","volume":"38","author":"Ette","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.13771_bb0125","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bja\/80.4.488","article-title":"Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics?","volume":"80","author":"Wright","year":"1998","journal-title":"Br J Anaesth"},{"key":"10.1111\/jth.13771_bb0130","unstructured":"US Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics. 1999. http:\/\/www.fda.gov\/downloads\/Drugs\/&\/Guidances\/UCM072137.pdf. Accessed 17 May 2016."},{"key":"10.1111\/jth.13771_bb0135","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jth.13771_bb0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2307\/2532087","article-title":"Nonlinear mixed effects models for repeated measures data","volume":"46","author":"Lindstrom","year":"1990","journal-title":"Biometrics"},{"key":"10.1111\/jth.13771_bb0145","unstructured":"R Core Team (2015). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. https:\/\/www.R-project.org\/."},{"key":"10.1111\/jth.13771_bb0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hae.12188","article-title":"Population pharmacokinetics of recombinant factor IX: implications for dose tailoring","volume":"19","author":"Bjorkman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0155","first-page":"107","article-title":"Nieuwe richtlijn diagnostiek en behandeling van hemofilie en aanverwante hemostasestoornissen","volume":"7","author":"Leebeek","year":"2010","journal-title":"Ned Tijdschr Hematol"},{"key":"10.1111\/jth.13771_bb0160","first-page":"33","article-title":"Clinical evaluation of recombinant factor IX","volume":"35","author":"White","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.13771_bb0165","unstructured":"Dubois A, Bertrand J, Mentre F. Mathematical expressions of the pharmacokinetic and pharmacodynamic models implemented in the PFIM software: INSERM & University Paris Diderot. 2011. http:\/\/www.pfim.biostat.fr\/PFIM_PKPD_library.pdf. Accessed 13 May 2016."},{"key":"10.1111\/jth.13771_bb0170","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"Suppl. 3","key":"10.1111\/jth.13771_bb0175","first-page":"1","article-title":"The pharmacokinetics of coagulation factors","volume":"12","author":"Lee","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0180","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","article-title":"Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma\u2010derived factor IX concentrates","volume":"98","author":"Roth","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.13771_bb0185","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/jth.12756","article-title":"Pharmacokinetic and pharmacodynamic properties of plasma\u2010derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study","volume":"12","author":"Alamelu","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1537-2995.2002.00039.x","article-title":"Pharmacokinetic analysis of plasma\u2010derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B","volume":"42","author":"Ewenstein","year":"2002","journal-title":"Transfusion"},{"key":"10.1111\/jth.13771_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2516.2010.02431.x","article-title":"A commentary on the differences in pharmacokinetics between recombinant and plasma\u2010derived factor IX and their implications for dosing","volume":"17","author":"Bjorkman","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2516.2003.00762.x","article-title":"The pharmacokinetics of clotting factor therapy","volume":"9","author":"Berntorp","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0205","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003088-200140110-00003","article-title":"Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia","volume":"40","author":"Bjorkman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13771_bb0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00228-012-1211-z","article-title":"Population pharmacokinetics of plasma\u2010derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis","volume":"68","author":"Bjorkman","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.13771_bb0215","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/hae.12216","article-title":"Pharmacokinetics of plasma\u2010derived and recombinant factor IX \u2013 implications for prophylaxis and on\u2010demand therapy","volume":"19","author":"Bjorkman","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2516.2006.01327.x","article-title":"Pharmacokinetic studies: international guidelines for the conduct and interpretation of such studies","volume":"12","author":"Morfini","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13771_bb0225","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1160\/TH16-10-0765","article-title":"Confirmation of longer FIX activity half\u2010life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B","volume":"117","author":"Hua","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13771_bb0230","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13771_bb0235","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half\u2010life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13771\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:17:16Z","timestamp":1761535036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622008637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1538783622008637"],"URL":"https:\/\/doi.org\/10.1111\/jth.13771","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}